Acorah Software Products - Accounts Production 16.5.460 false true false true No description of principal activity 24 April 2024 30 April 2025 30 April 2025 15674743 B Akay iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 15674743 2024-04-23 15674743 2025-04-30 15674743 2024-04-24 2025-04-30 15674743 frs-core:CurrentFinancialInstruments 2025-04-30 15674743 frs-bus:PrivateLimitedCompanyLtd 2024-04-24 2025-04-30 15674743 frs-bus:FilletedAccounts 2024-04-24 2025-04-30 15674743 frs-bus:Micro-entities 2024-04-24 2025-04-30 15674743 frs-bus:AuditExempt-NoAccountantsReport 2024-04-24 2025-04-30 15674743 frs-bus:Director1 2024-04-24 2025-04-30
Registered number: 15674743
ANGEL PHARMA LTD
Unaudited Financial Statements
For The Year Ended 30 April 2025
M.R Accountants Ltd
ANGEL PHARMA LTD
Balance Sheet
As At 30 April 2025
Balance Sheet
Registered number: 15674743

| 2025
--- | ---
|  | £
Current assets |  | 5,219
Creditors: Amounts Falling Due Within One Year |  | (5,070 )
NET CURRENT ASSETS |  | 149
TOTAL ASSETS LESS CURRENT LIABILITIES |  | 149
NET ASSETS |  | 149
CAPITAL AND RESERVES |  | 149

## Notes

1. General Information
ANGEL PHARMA LTD is a private company, limited by shares, incorporated in England & Wales, registered number 15674743 . The registered office is 9b The Broadway, Woodford Green, IG8 0HL.
2. Average Number of Employees
Average number of employees, including directors, during the year was: NIL
-
For the year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board

B Akay Director
11/09/2025